Highlights BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
28.01 ^USD	-2.91%		+0.25%	-30.62%

May. 29	Transcript : BridgeBio Pharma, Inc. - Special Call
May. 28	UBS Adjusts Price Target on BridgeBio Pharma to $47 From $51, Maintains Buy Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population	May. 13	CI
BridgeBio Pharma Shares Decline After Q1 Financial Results	May. 02	MT
Earnings Flash (BBIO) BRIDGEBIO PHARMA Posts Q1 Revenue $211.1M	May. 02	MT
BridgeBio Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance Imaging Evidence Consistent with Clinical Improvement	Apr. 07	CI
BridgeBio Pharma Sells License for Potential Heart Disease Treatment to Bayer in Deal Worth up to $310 Million	Mar. 04	MT
BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe	Mar. 04	RE
Bridgebio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM	Mar. 04	CI
BridgeBio Pharma Q4 Loss Widens as Revenue Declines	Feb. 22	MT
BridgeBio Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Earnings Flash (BBIO) BRIDGEBIO PHARMA Posts Q4 Revenue $1.7M	Feb. 22	MT
BridgeBio Pharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
KKR to acquire a stake in health tech firm Cotiviti	Feb. 14	RE
Bridgebio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan	Feb. 07	CI
BridgeBio Pharma Gets FDA Acceptance for NDA of Acoramidis	Feb. 05	DJ
BridgeBio Pharma, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy	Feb. 05	CI
BridgeBio Pharma, Inc. Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months	Feb. 02	CI
AstraZeneca: positive trial in cardiac amyloidosis	Feb. 02	CF
AstraZeneca celebrates latest successful trial of acoramidis in Japan	Feb. 02	AN
Invitae Collaborates With BridgeBio Pharma for Rare Disease Therapeutics	Jan. 30	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Highlights

Filters